CEL-SCI CORPORATION Stock Issued During Period, Value, Purchase of Assets
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CEL-SCI CORPORATION stock issued during period, value, purchase of assets for fiscal 2025 was $220.00K, a 172.88% increase from fiscal 2024.
- CEL-SCI CORPORATION stock issued during period, value, purchase of assets for fiscal 2024 was $80.62K.
| Period end | Stock Issued During Period, Value, Purchase of Assets 3 month | Stock Issued During Period, Value, Purchase of Assets 12 month |
|---|---|---|
| 2025-09-30 | $220.00K 10-K · filed 2025-12-29 | |
| 2024-09-30 | $80.62K 10-K · filed 2025-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |